🚀 go-pugleaf

Am I right in saying that this is a trial without blindness, controls
or placebo (just going from the abstract)? And presumably, the
clinical improvements cited are based on a neurologist's rating, 
not even blind (let alone objective, like finger tapping or
pronation-supination)? Lawks. 

Jeremy
-------------------------------------------------------
Jeremy Gauntlett-Gilbert
School of Psychology, 
University of St Andrews
St Andrews, Fife, 	tel:   (01334) 463053, x3053
KY16 9JU, Scotland   	email: jg3@st-and.ac.uk

:    Title
:           Nicotinamide adenine dinucleotide (NADH)--a new therapeutic
:           approach to Parkinson's disease. Comparison of oral and
:           parenteral application.
:    Author
:           Birkmayer JG; Vrecko C; Volc D; Birkmayer W
:    Address
:           Birkmayer-Institut f�r Parkinsontherapie Vienna, Austria.
:    Source
:           Acta Neurol Scand Suppl, 146:1993, 32-5
:    Abstract
:           The reduced coenzyme nicotinamide adenine dinucleotide (NADH)
:           has been used as medication in 885 parkinsonian patients in an
:           open label trial. About half of the patients received NADH by
:           intravenous infusion, the other part orally by capsules. In
:           about 80% of the patients a beneficial clinical effect was
:           observed: 19.3% of the patients showed a very good (30-50%)
:           improvement of disability, 58.8% a moderate (10-30%)
:           improvement. 21.8% did not respond to NADH. Statistical
:           analysis of the improvement in correlation with the disability
:           prior to treatment, the duration of the disease and the age of
:           the patients revealed the following results: All these 3
:           parameters have a significant although weak influence on the
:           improvement. The disability before the treatment has a positive
:           regression coefficient (t value < 0.01). The duration of the
:           disease has a negative regression coefficient (< 0.01) and so
:           has the age a negative regression coefficient (t value < 0.05).
:           In other words younger patients and patients with a shorter
:           duration of disease have a better chance to gain a marked
:           improvement than older patients and patients with longer
:           duration of the disease. The orally applied form of NADH
:           yielded an overall improvement in the disability which was
:           comparable to that of the parenterally applied form.
:           

: -- 


: Steve Emerson     semerson@teleport.com